医学
随机对照试验
安慰剂
评定量表
5-羟色胺再摄取抑制剂
萧条(经济学)
强迫症
汉密尔顿抑郁量表
临床试验
生活质量(医疗保健)
物理疗法
精神科
内科学
重性抑郁障碍
心理学
焦虑
心情
发展心理学
替代医学
抗抑郁药
经济
护理部
病理
宏观经济学
作者
Edna B. Foa,H. Blair Simpson,Thea Gallagher,Michael G. Wheaton,Marina Gershkovich,Andrew B. Schmidt,Jonathan D. Huppert,Patricia Imms,Raphael Campeas,Shawn P. Cahill,Christina DiChiara,Steven D. Tsao,Anthony C. Puliafico,Daniel Chazin,Anu Asnaani,Kelly Moore,Jeremy Tyler,Shari A. Steinman,Arturo Sanches-LaCay,Sandy Capaldi
出处
期刊:JAMA Psychiatry
[American Medical Association]
日期:2022-01-26
卷期号:79 (3): 193-193
被引量:16
标识
DOI:10.1001/jamapsychiatry.2021.3997
摘要
Serotonin reuptake inhibitors (SRIs) are the only medications approved for obsessive-compulsive disorder (OCD), yet most patients taking SRIs exhibit significant symptoms. Adding exposure/response prevention (EX/RP) therapy improves symptoms, but it is unknown whether patients maintain wellness after discontinuing SRIs.
科研通智能强力驱动
Strongly Powered by AbleSci AI